Literature DB >> 21881041

Do all patients with breast cancer require systemic adjuvant therapy?

Jennifer J Griggs, Daniel F Hayes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21881041      PMCID： PMC3176780          DOI： 10.1093/jnci/djr331

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  19 in total

Review 1.  Tamoxifen for early breast cancer.

Authors: 
Journal:  Cochrane Database Syst Rev       Date:  2001

2.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Authors:  Victor G Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin; Reena S Cecchini; James N Atkins; Therese B Bevers; Louis Fehrenbacher; Eduardo R Pajon; James L Wade; André Robidoux; Richard G Margolese; Joan James; Scott M Lippman; Carolyn D Runowicz; Patricia A Ganz; Steven E Reis; Worta McCaskill-Stevens; Leslie G Ford; V Craig Jordan; Norman Wolmark
Journal:  JAMA       Date:  2006-06-05       Impact factor: 56.272

3.  Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer.

Authors:  C Lindley; S Vasa; W T Sawyer; E P Winer
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

4.  Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy.

Authors:  P M Ravdin; I A Siminoff; J A Harvey
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

5.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors:  Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal:  N Engl J Med       Date:  2004-12-10       Impact factor: 91.245

6.  Effect of screening and adjuvant therapy on mortality from breast cancer.

Authors:  Donald A Berry; Kathleen A Cronin; Sylvia K Plevritis; Dennis G Fryback; Lauren Clarke; Marvin Zelen; Jeanne S Mandelblatt; Andrei Y Yakovlev; J Dik F Habbema; Eric J Feuer
Journal:  N Engl J Med       Date:  2005-10-27       Impact factor: 91.245

7.  Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less.

Authors:  Bernard Fisher; John Bryant; James J Dignam; D Lawrence Wickerham; Eleftherios P Mamounas; Edwin R Fisher; Richard G Margolese; Lois Nesbitt; Soonmyung Paik; Thomas M Pisansky; Norman Wolmark
Journal:  J Clin Oncol       Date:  2002-10-15       Impact factor: 44.544

8.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Authors: 
Journal:  Lancet       Date:  2005 May 14-20       Impact factor: 79.321

9.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

Authors:  B Fisher; J P Costantino; D L Wickerham; C K Redmond; M Kavanah; W M Cronin; V Vogel; A Robidoux; N Dimitrov; J Atkins; M Daly; S Wieand; E Tan-Chiu; L Ford; N Wolmark
Journal:  J Natl Cancer Inst       Date:  1998-09-16       Impact factor: 13.506

10.  Recurrence-free survival in patients with small breast cancer. An analysis of cancers 10 mm or less detected clinically and by screening.

Authors:  L G Arnesson; S Smeds; G Fagerberg
Journal:  Eur J Surg       Date:  1994-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.